Cardinal Health today announced a distribution agreement with
Biosensors that allows Cardinal Health's interventional
vascular business, Cordis, to sell Biosensors' coronary stents in select
countries outside of the U.S.
"We are very excited about this DES (drug-eluting stent) agreement with Biosensors, because it represents our strong commitment to expand our product portfolio to support the demands in cardiovascular care today," Cordis President David Wilson said. "While Cordis is known for developing product innovations, partnerships like this provide an opportunity to rapidly expand our unmatched portfolio and deliver increased value to customers and the patients they serve."
Biosensors' products are used in treating patients with coronary artery disease. Percutaneous coronary intervention (PCI) uses a stent to open blocked coronary arteries. The stent is placed in the artery with a catheter. This nonsurgical procedure using Biosensors stents is approved in Europe, Australia and New Zealand. Biosensors' drug-eluting stents are not approved for use in the U.S.
"I am proud of the role Cordis played in establishing the value of coronary stents many years ago," Wilson said. "Today, with Cordis' strong legacy and understanding of the DES market and the business and operational expertise of Cardinal Health, we have established an unmatched combined offering in the cardiovascular space."
Alerts Sign-up